NY-BORN
21.4.2021 15:14:06 CEST | Business Wire | Press release
Total global e-commerce sales represent over $25 trillion in value today, with B2B e-commerce global merchandise value representing more than $12 trillion (Statista). With close to 2 billion websites online as of January 2021, the process of navigating products and determining quality sources can be an arduous, time-consuming, and sometimes impossible task. With billions of individual products and brands represented online and the number of products only increasing by the minute, the importance of curation becomes a critical expertise to support digital transactions. Layer in the changing ways consumers make purchase decisions, including assessing sustainability, integrity, and purpose, and the importance of product strategy is perhaps more vital than ever.
The product curation process creates bespoke collections that appeal to specific demographics and niche customer groups. Modern product curation leverages customer segmentation data and purchase behavior information, followed by personalization techniques to drive product engagement and understanding, create supplemental content around products and ultimately increase transaction value. Today, BORN and Alkeon announce industry veteran Stewart Mancey as Director of E-Concession & Retail Partners, joining a deep bench of global experts from multiple categories. As Director of E-Concession & Retail Partners, Stewart will work closely with Pierre Sapin (Chief Partnership Officer), Brendan Wypich (Chief Design & Product Officer), and Jean-Christophe Chopin (CEO and Founder of BORN and former ex-Verisign and *ETrade EU founder) . Mancey will work with brands and retailers on both Alkeon and BORN. His prestigious training at Harrods and knowledge of the creativity behind each retailer will lead BORN to curate purpose-led lifestyle brands using the filters of integrity, functionality, and desirability.
Stewart states, “Twenty years at Harrods has given me a wonderful experience, fabulous industry contacts, and a deep understanding of the power of curation across multiple categories. As Head of Curation for BORN and Alkeon, I’ll guide the product strategy for both, carefully curating across multiple dimensions that reflect today’s buying priorities and creating the ideal mix representing a cross-section of the best products and companies in the world. We want to take a load of sifting off of buyers and consumers and allow them to experience best-in-class product discovery powered by machine learning, delivered in a personalized experience and a beautiful environment that leverages the latest in technology.”
Stewart started his successful buying career at Harrods when he moved from the shop floor in 2003, working through the buying office in Women’s Superbrands before becoming Buyer of Eveningwear, Armani, and Ralph Lauren after three years. He eventually moved over to Menswear in 2007, where he was Senior Buyer for Men’s Superbrands & Tailoring, overseeing over £10m in renovations and delivering strong growth throughout his four years. In 2011, Stewart added the title of Head of Buying for Sports and managed the London Olympic strategy for Harrods, along with an additional £5m renovation. In 2013, Stewart took over Head of Buying for Furniture, Technology, and Toys and increased his remit in 2017 to include Homewares. After 21 incredibly successful years with Harrods, Stewart today joins BORN and its B2B extension Alkeon. Stewart will be a key player in the vital balance between designed technology and brand culture within both BORN and Alkeon’s market networks.
CEO Jean-Christophe Chopin states, “ Our ambition across BORN and Alkeon is to transform the B2B and B2C supply chains, reimagining discovery, transaction, and connection for both communities. Stewart adds critical and unique expertise to our executive leadership, which is a collection of the best minds in curation, commerce, community, and content. Stewart will contribute his years of knowledge of culture and brands, his deep understanding of the chains of commerce across multiple categories, his leading editorial expertise, and his unmatched Rolodex of brands and creators. We are delighted to have him.”
About BORN:
BORN is a holding company specializing in digital, data-led solutions to optimize retail and wholesale supply chains and reimagine discovery and transactions online. BORN owns Alkeon, a suite of B2B solutions and software products that facilitate digital transformation, as well as BORN.com, a platform that connects a global network of design-led brands and retailers. BORN has also curated and hosted the BORN Awards for 10 years in celebration of purpose led products and creativity. BORN is led by CEO Jean-Christophe Chopin, ex-founder of *ETrade EU and Verisign EU.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom